Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05934513 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

StatusUnknown
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 13, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Lead sponsor: Zhejiang Genfleet Therapeutics Co., Ltd. to Genfleet Therapeutics (Shanghai) Inc.v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Sep 15, 2023 to Sep 6, 2023v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 15, 2023 to Sep 6, 2023
  5. Start date: Jul 30, 2023 to Sep 15, 2023 Primary endpoints revised (2) · Study title shortened, about 2 wordsv2 Show 2 more changesShow less
    • Primary endpoints revised (2)
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
Trial Details
NCT Number NCT05934513
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment 95 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov